

TIP-058-USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Tibotec Pharmaceuticals Ltd.

Serial No.:

Art Unit:

Filed :

Examiner:

For : COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH  
RT INHIBITORS

Commissioner for Patents  
Washington, D.C. 20231

CERTIFICATE UNDER 37 CFR 3.73(b)

Tibotec Pharmaceuticals Ltd., a Corporation, certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application identified above. The assignments were recorded in the Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), or the patent application identified above, to the current assignee as shown below:

1. From:  
To:  
The document was recorded in the Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

2. From:  
To:  
The document was recorded in the Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

3. From:  
To:

The document was recorded in the Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

24 January 2006  
Date

  
Signature

Frank Daelemans  
Typed or Printed Name

Proxy Holder  
Title